Federal Register #2026-16442

Licensing and Co-Development Opportunity: Human Anti-CE1 Antibodies for Liver Cancer Therapy

This opportunity from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) under the Department of Health and Human Services, offers a government-owned invention for license and co-development: - Government Buyer: - National Cancer Institute (NCI), NIH, Department of Health and Human Services - OEMs and Vendors: - National Cancer Institute (NCI) is the original developer and owner of the technology - Products/Services Requested: - Licensing and/or research co-development partnership for a collection of human anti-CE1 antibodies - Two human antibodies (B9 and B10) developed via phage display from a human scFv phage library - Target: Novel viral peptide associated with hepatocellular carcinoma (HCC), the most common adult liver cancer - Application: Therapeutic use in gastroenterology and oncology - NIH Reference Numbers: E0212025 and E0232024 - Unique or Notable Requirements: - Technology is at the pre-clinical stage - Antibodies have demonstrated specific binding to liver cancer cell lines and clinical tumor tissues - Preclinical studies show inhibition of tumor growth via NK cell-mediated antibody-dependent cellular cytotoxicity - Opportunity is for licensing and co-development, not for procurement of physical products - Issued under 37 CFR 404.4 (government technology licensing) - No specific purchase quantities or part numbers, as this is a licensing and R&D collaboration opportunity

Description

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees to develop a collection of anti-CE1 antibodies for liver cancer treatment. These antibodies target a novel viral peptide antigen associated with hepatocellular carcinoma (HCC), the most common liver cancer in adults. The antibodies have shown potential in inhibiting tumor growth through immune mechanisms in preclinical studies. This opportunity is aimed at advancing liver cancer therapeutics through licensing of this government-owned invention.

View original listing